Probiotics Anxiety Randomized Trial: What the Evidence Says

Quick Answer

Probiotics Anxiety Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• It is estimated that fibromyalgia can result in up to approximately 36 000$ of annual direct costs per patient in the US, imposing a considerable burden on the health care systems. [Nakhostin-Ansari Amin (2026); evidence level 1]
• The presence of these comorbid medical conditions can make the diagnosis of fibromyalgia challenging, which could lead to mismanagement, overtreatment, and increased drug side effects. [Nakhostin-Ansari Amin (2026); evidence level 1]
• The emerging evidence supports that there is a bidirectional relationship between gut microbiota and depression, representing a paradigm shift in psychiatric research. [Mosavat Seyed Hamdollah (2026); evidence level 2]
• Animal studies have presented some compelling evidence to suggest a causal role of dysbiosis in depression-like behaviours. [Mosavat Seyed Hamdollah (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For probiotics anxiety randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Nakhostin-Ansari Amin (2026). Effects of probiotics on psychological issues in people with fibromyalgia: a systematic review. DOI: 10.1097/MS9.0000000000004726. PMCID: PMC12959785. PMID: 41789223. License: https://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 This is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12959785/
• Mosavat Seyed Hamdollah (2026). Effect of probiotic supplement on improvement of depressive symptoms in patients with substance-induced depressive disorder: a randomized, double-blind, placebo-controlled clinical trial. DOI: 10.1186/s12888-026-07903-7. PMCID: PMC13097662. PMID: 41826906. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13097662/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.